Validation of Early Detection Ovarian Cancer Biomarkers (Team Project)
- Feng, Ziding — Fred Hutchinson Cancer Research Center
- Srivastava, Sudhir — National Cancer Institute
- Marks, Jeffrey — Duke University Medical Center
- Godwin, Andrew K — University of Kansas Medical Center
- Rodland, Karin — Pacific Northwest National Laboratory
- Urban, Nicole — Fred Hutchinson Cancer Research Center
- Li, Christopher — Fred Hutchinson Cancer Research Center
- Diamandis, Eleftherios P. — Mount Sinai Hospital
- Skates, Steven — Massachusetts General Hospital
Early detection of Ovarian Cancer (OC) is one of the key clinical problems in this disease. We propose a team EDRN project to address the issue of early detection of OC by performing a validation study on candidate protein markers already identified in previous EDRN research or in the literature (e.g. protein products of TCGA identified mutations specific to ovarian cancer). (See appendix for full listing) Biospecimen sources have been identified which include samples obtained at diagnosis and matched controls (Urban, Godwin, Marks, Skates), and longitudinal samples obtained prior to diagnosis (Urban, Skates, Godwin). Bioinformatic filters will be applied to rank the candidates (Diamandis). In order of ranking, candidate proteins for which high quality antibodies are available will be measured by development of ELISAs at JHU (Chan/Zhang) or through NAPPA at DFCI (Anderson/LaBaer), while for other candidates mass spectrometry based selective reaction monitoring (SRM) assays will be developed at PNNL (Rodland). Three milestones are defined. The first two milestones are to assemble the necessary specimens and to develop the qualifying assay(s). The final milestone is to estimate the markers’ sensitivity one year prior to diagnosis at a given high specificity.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.